We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 23, 2022

Effect of Canagliflozin on the Incidence of Atrial Fibrillation in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Diabetes Obes Metab 2022 Oct 01;24(10)1927-1938, C Li, J Yu, C Hockham, V Perkovic, BL Neuen, SV Badve, L Houston, VYJ Lee, JY Barraclough, RA Fletcher, KW Mahaffey, HJL Heerspink, CP Cannon, B Neal, C Arnott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading